Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel–Lindau protein

Article metrics

Abstract

von Hippel–Lindau (VHL) gene inactivation occurs in von Hippel–Lindau (VHL) disease. The protein pVHL functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Hif1α for proteasomal degradation during normoxia. We establish that pVHL binds to Tat-binding protein-1 (TBP-1), a component of the 19S regulatory complex of the proteasome. TBP-1 associates with the β-domain of pVHL and complexes with pVHL and Hif1α in vivo. Overexpression of TBP-1 promotes degradation of Hif1α in a pVHL-dependent manner that requires the ATPase domain of TBP-1. Blockade of TBP-1 expression by small interfering RNA (siRNA) causes prolonged degradation kinetics of Hif1α. Several distinct mutations in exon 2 of VHL disrupt binding of pVHL to TBP-1. A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1α, but not TBP-1, and does not promote degradation of Hif1α. Thus, the ability of pVHL to degrade Hif1α depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1α stabilization in some pVHL-deficient tumors.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: pVHL and TBP-1 interact.
Figure 2: TBP-1 is involved in the pVHL-mediated proteasomal degradation of Hif1α.
Figure 3: Reduced expression of TBP-1 results in delayed degradation kinetics of Hif1α.
Figure 4: Changes in TBP-1 expression do not affect basal expression levels of cellular proteins that are ubiquitinated by E3 ligases other than pVHL.
Figure 5: pVHL, TBP-1 and Hif1α subunits form a complex in vivo.
Figure 6: The β domain of pVHL interacts with the coiled-coil region of TBP-1 and select exon 2 pVHL mutants do not bind TBP-1.
Figure 7: Model of the effect of TBP-1 on pVHL-mediated degradation of Hif1α subunits by the proteasome in normoxia.

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. 1

    Kaelin, W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673–682 (2002).

  2. 2

    Herman, J.G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91, 9700–9704 (1994).

  3. 3

    Maxwell, P.H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).

  4. 4

    Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel–Lindau protein. Nat. Cell Biol. 2, 423–427 (2000).

  5. 5

    Stebbins, C.E., Kaelin, W.G. Jr. & Pavletich, N.P. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455–461 (1999).

  6. 6

    Kamura, T., Conrad, M.N., Yan, Q., Conaway, R.C. & Conaway, J.W. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev. 13, 2928–2933 (1999).

  7. 7

    Semenza, G.L. HIF-1 and human disease: one highly involved factor. Genes Dev. 14, 1983–1991 (2000).

  8. 8

    Ivan, M. et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 (2001).

  9. 9

    Jaakkola, P. et al. Targeting of HIF-α to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001).

  10. 10

    Bruick, R.K. & McKnight, S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337–1340 (2001).

  11. 11

    Epstein, A.C.R. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43–54 (2001).

  12. 12

    Gnarra, J.R. et al. Molecular cloning of the von Hippel–Lindau tumor suppressor gene and its role in renal carcinoma. Biochim. Biophys. Acta 1242, 201–210 (1996).

  13. 13

    Clifford, S.C. et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel–Lindau disease. Hum. Mol. Genet. 10, 1029–1038 (2001).

  14. 14

    Hoffman, M.A. et al. von Hippel–Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019–1027 (2001).

  15. 15

    Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P. & Krek, W. Regulation of microtubule stability by the von Hippel–Lindau tumour suppressor protein pVHL. Nat. Cell Biol. 5, 64–70 (2003).

  16. 16

    Ohh, M. et al. The von Hippel–Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1, 959–968 (1998).

  17. 17

    DeMartino, G.N. et al. Identification, purification, and characterization of a PA700-dependent activator of the proteasome. J. Biol. Chem. 271, 3112–3118 (1996).

  18. 18

    Nakamura, T., Tanaka, T., Takagi, H. & Sato, M. Cloning and heterogeneous in vivo expression of Tat binding protein-1 (TBP-1) in the mouse. Biochim. Biophys. Acta 1399, 93–100 (1998).

  19. 19

    Hoyle, J., Tan, K.H. & Fisher, E.M. Localization of genes encoding two human one-domain members of the AAA family: PSMC5 (the thyroid hormone receptor-interacting protein, TRIP1) and PSMC3 (the Tat-binding protein, TBP1). Hum. Genet. 99, 285–288 (1997).

  20. 20

    Braun, B.C. et al. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat. Cell Biol. 1, 221–226 (1999).

  21. 21

    Ferrell, K., Wilkinson, C.R., Dubiel, W. & Gordon, C. Regulatory subunit interactions of the 26S proteasome, a complex problem. Trends Biochem. Sci. 25, 83–88 (2000).

  22. 22

    Salceda, S. & Caro, J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272, 22642–22647 (1997).

  23. 23

    Rubin, D.M., Glickman, M.H., Larsen, C.N., Dhruvakumar, S. & Finley, D. Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome. EMBO J. 17, 4909–4919 (1998).

  24. 24

    Sung, P., Higgins, D., Prakash, L. & Prakash, S. Mutation of lysine-48 to arginine in the yeast RAD3 protein abolishes its ATPase and DNA helicase activities but not the ability to bind ATP. EMBO J. 7, 3263–3269 (1988).

  25. 25

    Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25–27 (1997).

  26. 26

    Strohmaier, H. et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413, 316–322 (2001).

  27. 27

    Sudakin, V. et al. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol. Biol. Cell 6, 185–197 (1995).

  28. 28

    Zachariae, W., Shin, T.H., Galova, M., Obermaier, B. & Nasmyth, K. Identification of subunits of the anaphase-promoting complex of Saccharomyces cerevisiae. Science 274, 1201–1204 (1996).

  29. 29

    Gnarra, J.R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85–90 (1994).

  30. 30

    Whaley, J.M. et al. Germ-line mutations in the von Hippel–Lindau tumor- suppressor gene are similar to somatic von Hippel–Lindau aberrations in sporadic renal cell carcinoma. Am. J. Hum. Mol. Genet. 55, 1092–1102 (1994).

  31. 31

    Crossey, P.A. et al. Identification of intragenic mutations in the von Hippel–Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum. Mol. Genet. 3, 1303–1308 (1994).

  32. 32

    Hon, W.C. et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417, 975–978 (2002).

  33. 33

    Liu, C.W. et al. Conformational remodeling of proteasomal substrates by PA700, the 19S regulatory complex of the 26S proteasome. J. Biol. Chem. 277, 26815–26820 (2002).

  34. 34

    Xie, Y. & Varshavsky, A. UFD4 lacking the proteasome-binding region catalyses ubiquitination but is impaired in proteolysis. Nat. Cell Biol. 4, 1003–1007 (2002).

  35. 35

    Iliopoulos, O. et al. Negative regulation of hypoxia-inducible genes by the von Hippel–Lindau protein. Proc. Natl. Acad. Sci. USA 93, 10595–10599 (1996).

  36. 36

    He, T.C. et al. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95, 2509–2514 (1998).

  37. 37

    Gardner, L.B. et al. Hypoxia inhibits G1/S transition through regulation of p27 expression. J. Biol. Chem. 276, 7919–7926 (2001).

  38. 38

    Elbashir, S.M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 (2001).

Download references

Acknowledgements

The authors thank M. Rountree and K. Bachman for technical assistance with the yeast two-hybrid assay in the initial phase of this study and C. Stolle for clinical information on individuals with VHL disease. This work was supported by grants from the US National Institutes of Health and by the Howard Hughes Medical Institute. W.S.E-D. is an Assistant Investigator of the Howard Hughes Medical Institute.

Author information

Correspondence to Wafik S El-Deiry.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Further reading